$GRCE

2022 Q4 Form 10-Q Financial Statement

#000095017022024666 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.795M $1.816M $2.982M
YoY Change -12.27% -39.1% 104.53%
% of Gross Profit
Research & Development $2.450M $3.292M $585.0K
YoY Change 12.44% 462.74% -54.51%
% of Gross Profit
Depreciation & Amortization $10.00K -$61.00K $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $4.245M $5.108M $3.567M
YoY Change 0.47% 43.2% 29.99%
Operating Profit -$4.245M -$5.108M -$3.567M
YoY Change -5.12% 43.2% -55.6%
Interest Expense $79.00K -$12.00K $4.548M
YoY Change -88.65% -100.26% 124.04%
% of Operating Profit
Other Income/Expense, Net $82.00K $24.00K $4.548M
YoY Change -88.22% -99.47% 140.89%
Pretax Income -$4.163M -$5.084M $981.0K
YoY Change 10.19% -618.25% -115.96%
Income Tax -$274.0K $155.0K $0.00
% Of Pretax Income 0.0%
Net Earnings -$3.889M -$4.929M $981.0K
YoY Change 2.94% -602.45% -115.96%
Net Earnings / Revenue
Basic Earnings Per Share -$0.09 -$0.11 -$0.03
Diluted Earnings Per Share -$0.09 -$0.11 $29.92K
COMMON SHARES
Basic Shares Outstanding 44.61M 44.49M 208.4M
Diluted Shares Outstanding 44.61M 44.55M 32.79M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $31.26M $34.94M $50.79M
YoY Change -32.53% -31.21% 339.66%
Cash & Equivalents $26.24M $34.93M $36.93M
Short-Term Investments $5.015M $14.00K $13.86M
Other Short-Term Assets $1.394M $1.706M $2.942M
YoY Change -42.73% -42.01% 91.54%
Inventory
Prepaid Expenses $1.042M $1.354M $2.178M
Receivables $778.0K $859.0K $813.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $33.43M $37.51M $54.55M
YoY Change -31.78% -31.24% 297.76%
LONG-TERM ASSETS
Property, Plant & Equipment $599.0K $632.0K $43.00K
YoY Change 2622.73% 1369.77% -63.87%
Goodwill $12.96M $12.96M
YoY Change
Intangibles $69.81M $69.81M $65.21M
YoY Change 7.06% 7.06%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $83.37M $83.41M $65.25M
YoY Change 27.81% 27.82% 54732.77%
TOTAL ASSETS
Total Short-Term Assets $33.43M $37.51M $54.55M
Total Long-Term Assets $83.37M $83.41M $65.25M
Total Assets $116.8M $120.9M $119.8M
YoY Change 2.25% 0.93% 766.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.360M $3.735M $4.433M
YoY Change 18.19% -15.75% 20.79%
Accrued Expenses $73.00K $70.00K $43.00K
YoY Change 231.82% 62.79% -46.91%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.433M $3.805M $4.476M
YoY Change 18.5% -14.99% 19.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $430.0K $450.0K $1.116M
YoY Change 60.45% -59.68% -7.62%
Total Long-Term Liabilities $430.0K $450.0K $1.116M
YoY Change 60.45% -59.68% -7.62%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.433M $3.805M $4.476M
Total Long-Term Liabilities $430.0K $450.0K $1.116M
Total Liabilities $20.08M $20.75M $5.592M
YoY Change 534.47% 271.01% 12.76%
SHAREHOLDERS EQUITY
Retained Earnings -$169.2M -$165.3M -$148.2M
YoY Change 11.35% 11.57% 8.02%
Common Stock $258.3M $258.3M $258.0M
YoY Change 0.12% 0.12% 80.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $96.72M $100.2M $114.2M
YoY Change
Total Liabilities & Shareholders Equity $116.8M $120.9M $119.8M
YoY Change 2.25% 0.93% 766.08%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$3.889M -$4.929M $981.0K
YoY Change 2.94% -602.45% -115.96%
Depreciation, Depletion And Amortization $10.00K -$61.00K $0.00
YoY Change -100.0%
Cash From Operating Activities -$3.722M -$3.439M -$6.104M
YoY Change -18.8% -43.66% 46.1%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$2.000K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$5.001M -$94.00K $2.837M
YoY Change -997.85% -103.31%
Cash From Investing Activities -$5.001M -$96.00K $2.837M
YoY Change -997.85% -103.38% -8696.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 109.0K $0.00
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -3.722M -3.439M -$6.104M
Cash From Investing Activities -5.001M -96.00K $2.837M
Cash From Financing Activities 0.000 109.0K $0.00
Net Change In Cash -8.723M -3.426M -$4.046M
YoY Change 122.75% -15.32% 609.82%
FREE CASH FLOW
Cash From Operating Activities -$3.722M -$3.439M -$6.104M
Capital Expenditures $0.00 -$2.000K $0.00
Free Cash Flow -$3.722M -$3.437M -$6.104M
YoY Change -18.8% -43.69% 47.26%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Other Income
OtherIncome
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Other Income
OtherIncome
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
dei Entity Central Index Key
EntityCentralIndexKey
0001444192
dei Amendment Flag
AmendmentFlag
false
acst Write Off Of Equipment
WriteOffOfEquipment
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2022Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
us-gaap Investment Income Interest
InvestmentIncomeInterest
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5084000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
us-gaap Depreciation
Depreciation
us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35776
dei Entity Registrant Name
EntityRegistrantName
Acasti Pharma Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
Z4
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1359336
dei Entity Address Address Line1
EntityAddressAddressLine1
3009 boul. de la Concorde East, Suite 102
dei Entity Address City Or Town
EntityAddressCityOrTown
Laval
dei Entity Address State Or Province
EntityAddressStateOrProvince
QC
dei Entity Address Country
EntityAddressCountry
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
H7E 2B5
dei City Area Code
CityAreaCode
450
dei Local Phone Number
LocalPhoneNumber
686-4555
dei Security12b Title
Security12bTitle
Common Shares, no par value per share
dei Trading Symbol
TradingSymbol
ACST
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
44612831
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34926000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30339000
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
14000
CY2022Q1 us-gaap Short Term Investments
ShortTermInvestments
13322000
CY2022Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
859000
CY2022Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
548000
CY2022Q3 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
352000
CY2022Q1 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
352000
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1354000
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
720000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
37505000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
45281000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
510000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
315000
CY2022Q3 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
122000
CY2022Q1 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
250000
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
69810000
CY2022Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
69810000
CY2022Q3 us-gaap Goodwill
Goodwill
12964000
CY2022Q1 us-gaap Goodwill
Goodwill
12964000
CY2022Q3 us-gaap Assets
Assets
120911000
CY2022Q1 us-gaap Assets
Assets
128620000
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3735000
CY2022Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3156000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
70000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
104000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3805000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3260000
CY2022Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0
CY2022Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
10000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
450000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
191000
CY2022Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
16492000
CY2022Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
16889000
CY2022Q3 us-gaap Liabilities
Liabilities
20747000
CY2022Q1 us-gaap Liabilities
Liabilities
20350000
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
258294000
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
257990000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
13200000
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
12154000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6040000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6037000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-165290000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-155837000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
100164000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
108270000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
120911000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
128620000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3292000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
585000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5882000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1054000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1680000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2957000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3598000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5633000
CY2022Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
136000
CY2021Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
25000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
357000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
25000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5108000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3567000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9837000
us-gaap Operating Income Loss
OperatingIncomeLoss
-6712000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
24000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4548000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-13000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4575000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
981000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9850000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2137000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
155000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
397000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-4929000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
981000
us-gaap Net Income Loss
NetIncomeLoss
-9453000
us-gaap Net Income Loss
NetIncomeLoss
-2137000
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44550996
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44550996
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32788275
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32788275
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44440132
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44440132
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29436032
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29436032
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
108270000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4524000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2000
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
195000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
464000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
104403000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-4929000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
109000
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
582000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
100164000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
55660000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3118000
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
762000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
153000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
53457000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
981000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1149000
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
114000
CY2021Q3 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
60801000
us-gaap Net Income Loss
NetIncomeLoss
-2137000
us-gaap Depreciation
Depreciation
106000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
114204000
us-gaap Net Income Loss
NetIncomeLoss
-9453000
us-gaap Share Based Compensation
ShareBasedCompensation
1046000
us-gaap Share Based Compensation
ShareBasedCompensation
267000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-10000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4080000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
397000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
51000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-420000
acst Write Off Of Equipment
WriteOffOfEquipment
31000
acst Increase Decrease In Working Capital
IncreaseDecreaseInWorkingCapital
137000
acst Increase Decrease In Working Capital
IncreaseDecreaseInWorkingCapital
3135000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8865000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9505000
us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
9000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
14000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
21528000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
13185000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
17438000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13162000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4090000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
304000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
304000
acst Effect Of Translation Effect On Cash And Cash Equivalents
EffectOfTranslationEffectOnCashAndCashEquivalents
156000
acst Effect Of Translation Effect On Cash And Cash Equivalents
EffectOfTranslationEffectOnCashAndCashEquivalents
-312000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-170000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-106000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4587000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14013000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
30339000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
50942000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
34926000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36929000
CY2022Q3 us-gaap Cash
Cash
34926000
CY2021Q3 us-gaap Cash
Cash
36929000
CY2022Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2021Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-left:1.2%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. Nature of operation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span> </p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acasti Pharma Inc. (“Acasti” or the “Corporation”) is incorporated under the Business Corporations Act (Québec) (formerly Part 1A of the Companies Act (Québec)). The Corporation is domiciled in Canada and its registered office is located at 3009 boul. de la Concorde East, Suite 102, Laval, Québec, Canada H7E 2B5.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span> </p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2021, the Corporation completed the acquisition via a share-for-share merger of Grace Therapeutics, Inc. (“Grace”), a privately held emerging biopharmaceutical company focused on developing innovative drug delivery technologies for the treatment of rare and orphan diseases. The post-merger Corporation is focused on building a late-stage specialty pharmaceutical company specializing in rare and orphan diseases and developing and commercializing products that improve clinical outcomes using our novel drug delivery technologies. The Corporation seeks to apply new proprietary formulations to existing pharmaceutical compounds to achieve enhanced efficacy, faster onset of action, reduced side effects, more convenient delivery and increased patient compliance; all of which could result in improved patient outcomes. The active pharmaceutical ingredients chosen by the Corporation for further development may be already approved in the target indication or could be repurposed for use in new indications.</span></p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span> </p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Corporation has incurred operating losses and negative cash flows from operations in each year since its inception. The Corporation expects to incur significant expenses and continued operating losses for the foreseeable future. The Corporation expects its expenses will increase substantially in connection with its ongoing activities, particularly as it advances clinical development for the first three drug candidates in the Corporation’s pipeline; continues to engage contract manufacturing organizations (“CMOs”) to manufacture its clinical study materials and to ultimately develop large-scale manufacturing capabilities in preparation for commercial launch; seeks regulatory approval for its drug candidates; and adds personnel to support its drug product development and future drug product launch and commercialization.</span></p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span> </p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Corporation does not expect to generate revenue from product sales unless and until it successfully completes drug development and obtains regulatory approval, which the Corporation expects will take several years and is subject to significant uncertainty. To date, the Corporation has financed its operations primarily through public offerings and private placements of its common shares, warrants and convertible debt and the proceeds from research tax credits. Until such time that the Corporation can generate significant revenue from drug product sales, if ever, it will require additional financing, which is expected to be sourced from a combination of public or private equity or debt financings or other non-dilutive sources, which may include fees, milestone payments and royalties from collaborations with third parties. Arrangements with collaborators or others may require the Corporation to relinquish certain rights related to its technologies or drug product candidates. Adequate additional financing may not be available to the Corporation on acceptable terms, or at all. The Corporation’s inability to raise capital as and when needed could have a negative impact on its financial condition and its ability to pursue its business strategy.</span></p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span> </p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Corporation remains subject to risks similar to other development stage companies in the biopharmaceutical industry, including compliance with government regulations, protection of proprietary technology, dependence on third party contractors and consultants and potential product liability, among others.</span></p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span> </p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Reverse stock split</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span> </p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 26, 2021, the shareholders of the Corporation approved a resolution to undertake a reverse split of the common stock within a range of 1-6 to 1-8 with such specific ratio to be approved by the Acasti Board. All references in these financial statements to number of common shares, warrants and options, price per share and weighted average number of shares outstanding prior to the reverse split have been adjusted to reflect the approved reverse stock split of 1-</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which was made effective on August 31, 2021, on a retroactive basis as of the earliest period presented.</span></p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span> </p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of these financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, income, and expenses. Actual results may differ from these estimates.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span> </p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimates are based on management’s best knowledge of current events and actions that management may undertake in the future. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</span></p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span> </p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimates and assumptions include the measurement of derivative warrant liabilities (note 7), stock-based compensation (note 10), assets held for sale (note 6), supply agreement (note 12), valuation of intangibles (note 4) and goodwill. Estimates and assumptions are also involved in measuring the accrual of services rendered with respect to research and development expenditures at each reporting date, including whether contingencies should be accrued for, as well as in determining which research and development expenses qualify for investment tax credits and in what amounts. The Corporation recognizes the tax credits once it has reasonable assurance that they will be realized. Recorded tax credits are subject to review and approval by tax authorities and, therefore, could be different from the amounts recorded.</span></p>
CY2022Q3 us-gaap Marketable Securities
MarketableSecurities
14000
CY2022Q1 us-gaap Marketable Securities
MarketableSecurities
13322000
CY2022Q2 acst Disposal Group Including Discontinued Operation Property Plant And Equipment Cost
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCost
696000
CY2022Q2 acst Disposal Group Including Discontinued Operation Property Plant And Equipment Accumulated Depreciation
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentAccumulatedDepreciation
446000
CY2022Q2 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
-250000
CY2022Q2 us-gaap Depreciation Expense On Reclassified Assets
DepreciationExpenseOnReclassifiedAssets
167000
CY2019Q1 acst Atthemarket Sales Agreement Common Stock Maximum Amount
AtthemarketSalesAgreementCommonStockMaximumAmount
30000000
CY2019Q1 acst Atthemarket Sales Agreement Term
AtthemarketSalesAgreementTerm
P3Y
CY2020Q2 acst Atthemarket Sales Agreement Common Stock Maximum Amount
AtthemarketSalesAgreementCommonStockMaximumAmount
75000000
CY2020Q2 acst Atthemarket Sales Agreement Underwriter Fees Percentage Of Sales
AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales
0.030
CY2019Q1 acst Write Off Of Deferred Financing Costs Of At The Market Program
WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram
115000
CY2021Q4 acst Atthemarket Sales Agreement Common Stock Maximum Amount
AtthemarketSalesAgreementCommonStockMaximumAmount
75000000
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
32390
CY2022Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
161000
CY2022Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
32390
CY2022Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
161000
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-12000
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
1099000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-90000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
344000
CY2021Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3435000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-10000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4080000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
14000
us-gaap Investment Income Interest
InvestmentIncomeInterest
151000
CY2022Q3 us-gaap Other Income
OtherIncome
36000
us-gaap Other Income
OtherIncome
67000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
24000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4548000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-13000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4575000
CY2022Q3 acst Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice
0.80
acst Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice
1.10
CY2022Q3 acst Shares Price
SharesPrice
0.80
acst Shares Price
SharesPrice
1.10
CY2022Q3 acst Share Based Compensation Arrangement By Share Based Payment Award Option Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionNonvestedWeightedAverageGrantDateFairValue
0.67
acst Share Based Compensation Arrangement By Share Based Payment Award Option Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionNonvestedWeightedAverageGrantDateFairValue
0.94
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.1796
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.1756
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0320
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0328
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y3M7D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y8M23D
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-359000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-287000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-704000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1838000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
926000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1010000
acst Increase Decrease In Non Cash Working Capital
IncreaseDecreaseInNonCashWorkingCapital
-137000
acst Increase Decrease In Non Cash Working Capital
IncreaseDecreaseInNonCashWorkingCapital
-3135000

Files In Submission

Name View Source Status
0000950170-22-024666-index-headers.html Edgar Link pending
0000950170-22-024666-index.html Edgar Link pending
0000950170-22-024666.txt Edgar Link pending
0000950170-22-024666-xbrl.zip Edgar Link pending
acst-20220930.htm Edgar Link pending
acst-20220930.xsd Edgar Link pending
acst-ex31_1.htm Edgar Link pending
acst-ex31_2.htm Edgar Link pending
acst-ex32_1.htm Edgar Link pending
acst-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img179499182_0.jpg Edgar Link pending
img179499182_1.jpg Edgar Link pending
img179499182_10.jpg Edgar Link pending
img179499182_11.jpg Edgar Link pending
img179499182_2.jpg Edgar Link pending
img179499182_3.jpg Edgar Link pending
img179499182_4.jpg Edgar Link pending
img179499182_5.jpg Edgar Link pending
img179499182_6.jpg Edgar Link pending
img179499182_7.jpg Edgar Link pending
img179499182_8.jpg Edgar Link pending
img179499182_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
acst-20220930_def.xml Edgar Link unprocessable
acst-20220930_lab.xml Edgar Link unprocessable
acst-20220930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
acst-20220930_htm.xml Edgar Link completed
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
acst-20220930_cal.xml Edgar Link unprocessable